Key Findings
- Caris MI Clarity™ BCR showed strong, independent prognostic performance for both late and overall distant recurrence (DR) risk in the TAILORx cohort, with meaningful risk stratification up to 15 years.
- The model remained prognostic after adjustment for clinical and genomic factors, demonstrating discrimination comparable to or better than existing tools across multiple analyses.
- Together with prior NSABP B-42 results, these findings support the potential clinical utility of Caris MI Clarity BCR to inform long-term treatment decisions for patients with HR+ early breast cancer.